The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features upcoming oral presentations by MD Anderson researchers at the European Society for Medical Oncology (ESMO) Congress 2022 focused on clinical advances across a variety of cancer types. Highlights include promising early data from a novel T cell therapy for solid tumors, targeted therapy progress in rare and advanced cancers, biomarkers of immunotherapy response, and features associated with clinical outcomes in leptomeningeal disease. More information on ESMO content from MD Anderson can be found at MDAnderson.org/ESMO.
Tag: Investigational Cancer Therapeutics
KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial
For patients with advanced solid cancers and KRAS G12C mutations, the targeted therapy sotorasib, a KRAS G12C inhibitor, resulted in manageable toxicities and durable clinical benefits, particularly in lung and colorectal cancer, in Phase I study
Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial.
Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
In a Phase II trial led by MD Anderson researchers, a combination targeted therapy acheived a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.
MD Anderson and Philips collaborate to facilitate personalized oncology treatments and clinical trial matching based on genomic markers
MD Anderson and Philips today announced a collaboration to aid oncologists around the world to personalize therapy based on their patients’ genomic profiles, with the aim of improving patient care.
MD Anderson and Ipsen advance new therapy with potential benefit for underserved patients with lung and ovarian cancer
MD Anderson and Ipsen have advanced a new targeted therapy into clinical trials for certain patients with lung and ovarian cancers. Details are being presented at the AACR Annual Meeting.
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers
Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers. Open-label Phase II study at MD Anderson reports on four cancer types.